New PBAC application supports immunotherapy treatment for oesophageal and gastro-oesophageal junction cancers

Tamara Grigg

Pancare is supporting Bristol Meyers Squibb in their application to the Pharmaceutical Benefits Advisory Committee (PBAC) for the funding of Nivolumab, an immunotherapy for the treatment of

Implantable drug-eluting device: pancreatic cancer research update

Linda Kerr

This multidisciplinary research collaboration has brought together leaders in Cancer Biology and Therapeutics, Oncology, and Biomedical Material Science in a project that has developed a novel drug